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Abstract
Purpose To better understand the mechanisms underlying
(in)sensitivity of tumors to anticancer drugs, assessing
intra-tumor drug pharmacokinetics (PKs) could be impor-
tant. We explored the feasibility of microdialysis in tumor
tissue for multiple days in a clinical setting, using carbo-
platin as model drug.
Methods Plasma and microdialysate samples from tumor
and adipose normal tissues were collected up to 47 h after
dosing in eight carboplatin-treated patients with an acces-
sible (sub)cutaneous tumor.
Results Pharmacokinetics were evaluable in tumor tissue
in 6/8 patients and in adipose normal tissue in 3/8 patients.
Concentration–time curves of unbound platinum in both
the tissues followed the pattern of the curves in plasma,
with exposure ratios of tissue versus plasma ranging from
0.64 to 1.46.
Conclusions Microdialysis can be successfully employed
in ambulant patients for multiple days, which enables one
to study tissue PK of anticancer drugs in normal and
malignant tissues in more detail.
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Introduction
In clinical oncology, many treatment regimens are in part
based on acquired concentrations of the involved anticancer
drugs measured in blood. This so-called pharmacokinetic
(PK) proﬁle in the peripheral circulation has been estab-
lished for many of the currently used cytotoxic drugs, but
varies largely between patients because of inter-individual
differences in capacity to metabolize and eliminate the
administered agent. Furthermore, the obtained blood PK
proﬁle may not be informative enough or may not, per
deﬁnition, be related to tumor or tissue concentrations. This
was demonstrated, e.g., in mice-bearing tumor xenografts
treated with docetaxel, camptothecin analogues and topo-
tecan, respectively, where plasma, tissue and tumor
concentrations differed considerably [1–3]. Also, clinical
parameters such as drug efﬁcacy and toxicity are quite often
not concordantly associated. Consequently, it would be
interesting to gain more information about the pharmaco-
kinetic processes at the tumor site itself.
The technique of microdialysis allows for the evaluation
of tumor and tissue disposition of drugs. Microdialysis is a
minimally invasive sampling method based on the diffu-
sion of analytes from the interstitial compartment [i.e.
extracellular ﬂuid (ECF)] through a semipermeable mem-
brane. After inserting a microdialysis catheter into the
selected tissue followed by perfusion with an isotonic ﬂuid,
the perfusate, the exchange of endogenous and/or exoge-
nous compounds from the ECF into the perfusate takes
place following their concentration gradient. The solution
that exits the catheter, the microdialysate, is then collected
for analysis (Fig. 1a). Since there is no net ﬂuid exchange
over the membrane during microdialysis, continuous
sampling for prolonged periods is possible without inter-
fering with the pharmacokinetic behavior of the drug [4].
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rological research where microdialysis was used to monitor
neurotransmitter concentrations in brain tissue. Microdi-
alysis was shown to be applicable in oncology as well.
Clinical drug disposition studies using microdialysis were
performed with several anticancer drugs, such as 5-ﬂuo-
rouracil [5], capecitabine [6], cisplatin [7], carboplatin [8],
dacarbazine [9] and methotrexate [10, 11].
However, in these studies with anticancer drugs per-
formed till now, the pharmacokinetic data derived using
microdialysis were collected only during a relative short
period of time, i.e. up to a maximum of 4 h, which might be
too short to obtain informative pharmacokinetic proﬁles.
Therefore, in the present study, the feasibility of microdi-
alysiswasstudiedformultipledays.Carboplatinwaschosen
as model drug since this drug exists in two distinguishable
fractions in the plasma compartment: the free fraction dis-
solved in plasma water (i.e. unbound fraction), which is
thought to penetrate tissues, and the irreversibly to plasma
protein bound fraction. Given the relative slow plasma
clearance of the unbound fraction of carboplatin [12]i n
comparison with for example the unbound fraction of the
other widely used platinum containing anticancer agent
cisplatin, it was expected that carboplatin-derived platinum
concentrations could be quantitated in the dialysates for
severaldaysaftertheadministration.Investigationofnormal
tissue was conducted as well to compare the data obtained
through microdialysis with PK data from the tumor site.
Patients and methods
Patient selection criteria
Patients who had a (sub)cutaneous primary tumor or
metastasis and for whom carboplatin-based therapy was a
viable treatment option were eligible for the study. The
(sub)cutaneous lesion had to be of sufﬁcient size (i.e.
C20 mm) and readily accessible for catheter implanta-
tion. Other inclusion criteria included: no use of
therapeutic doses of anticoagulants (prophylactic use was
allowed); no previous serious allergic reactions to plati-
num compounds; WHO performance status B1; age
C18 years; absolute neutrophil count C1.5 9 10
9 L
-1;
absolute platelet count C100 9 10
9 L
-1; creatinine
clearance C60 mL/min; no other serious illness or
medical unstable condition requiring treatment or history
of psychiatric disorder that would prohibit the under-
standing and giving of informed consent. This single-
center study was approved by the ethical committee of
the Erasmus Medical Center (Rotterdam, the Nether-
lands) and was performed in accordance with the
standards laid down in the 1964 Declaration of Helsinki
and its later amendments. All patients gave written
informed consent.
Administration of carboplatin
Carboplatin (Carbosin, Pharmachemie, Haarlem, the
Netherlands) was administered as a 1 h intravenous infu-
sion at an AUC of 6 (mg min)/mL based on the Calvert
formula [13]. To prevent allergic reactions and nausea and
vomiting, a premedication schedule consisting of dexa-
methasone, clemastine, ranitidine and granisetron was
administered intravenously prior to the start of the carbo-
platin infusion. In case carboplatin was combined with
another cytotoxic agent (e.g. paclitaxel), this second agent
was administered approximately 48 h after the adminis-
tration of carboplatin.
Plasma pharmacokinetic and microdialysis sampling
were performed during a single treatment course.
Fig. 1 Schematic representation of a microdialysis probe and the diffusion path of an analyte in tissue (a) and microdialysis instruments (b)
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The microdialysis catheters (CMA 70, brain catheters),
pumps (CMA 107, ﬂow rate adjustable) and microdialysis
consumables were purchased from CMA/Microdialysis
AB (Solna, Sweden; Fig. 1b). The applied microdialysis
instruments were, at least at start of the clinical study, the
only CE-labeled devices according to the Medical Device
Directive (MDD) for the use in peripheral tissue and have
been approved for clinical use. Prior to catheter insertion,
the surface of the skin was locally anaesthetized with
topical lidocaine/prilocaine cream and thereafter disin-
fected according to local procedures. Microdialysis
catheter insertion took place according to the procedure
previously described by Mu ¨ller et al. [14]. Each patient
had one microdialysis catheter inserted in a suitable
(sub)cutaneous tumor lesion and a second one into heal-
thy abdominal subcutaneous adipose tissue. Correct
positioning of the catheter at the tumor site was deter-
mined by ultrasound.
After implantation, the microdialysis syringe was ﬁlled
with 2.5 mL of Ringer’s solution (147 mmol/L Na
?,
2.25 mmol/L Ca
2?, 4.00 mmol/L K
?, and 156 mmol/L Cl;
Baxter, Utrecht, the Netherlands), connected to the
microdialysis catheter and then placed in the pump. The
pump automatically started with a 5–6-min ﬂush period
(ﬂow 15 lL/min) after which the ﬂow automatically
decreased to the preset ﬂow rate of 0.5 lL/min.
Since implantation of the microdialysis catheter could
cause adverse tissue reactions (i.e. inﬂammatory effects),
the catheter was implanted the day before the carboplatin
infusion to allow enough time to let these tissue reactions
subside [15]. Earlier studies showed that the minimally
invasive technique of microdialysis implantation has gen-
erally no effect on the performance of the implanted
microdialysis catheters [14–16]. Sampling with microdi-
alysis probes was started on the day of implantation (day 0)
and up to a maximum of 48 h after carboplatin infusion.
Carboplatin infusion was started 2 h after the recovery
determination on day 1, during which time period carbo-
platin was washed out from the periprobe ﬂuid (data not
shown). Figure 2 depicts the order of procedures under-
taken in this study.
Assessment of probe recovery
As microdialysis is not performed under equilibrium
conditions, the concentration of the drug in the dialysate
will be different from that in the ﬂuid around the probe
(i.e. in the tissue of investigation). The relationship
between the dialysate concentration and the concentra-
tion around the probe is called relative recovery [17],
which can be depicted in a ratio. As the rates of
diffusion of most analytes differ between aqueous solu-
tions and tissue, adequate validation of the in vivo
recovery is required. Solely in vitro calibration of a
microdialysis probe is insufﬁcient, but is useful to
investigate (a) the potential absorption of analyte to the
microdialysis probe [18] and (b) the potential effect of
the analyte concentration, at clinically relevant concen-
trations, on the recovery.
The in vitro recovery of the CMA 70 catheters was
assessed at ambient temperature using the extraction
recovery (Eq. 1) as well as the retrodialysis (Eq. 2)
method:
Recovery ¼ Concdialysate=Concsolution   100% ð1Þ
Recovery ¼ð Concperfusate   ConcdialysateÞ=Concperfusate
  100% ð2Þ
Using the extraction recovery method, the recovery was
determined at concentrations of 2.0 and 20 lg/mL
carboplatin (Carbosin, Pharmachemie, Haarlem, the
Netherlands) in Ringer’s solution at a ﬂow rate of
0.5 lL/min, at a concentration of 20 lg/mL carboplatin
at ﬂow rates of 0.5, 1.0 and 2.0 lL/min and at a
concentration of 20 lg/mL carboplatin at a ﬂow rate of
0.5 lL/min during 3 days. Using the retrodialysis method,
the recovery was assessed at a concentration of 20 lg/mL
carboplatin at a ﬂow rate of 0.5 lL/min. Three consecutive
30 min samples were taken for each experiment after an
equilibration time of at least 30 min. Samples were stored
at T\-20C until analysis.
The in vivo recovery for each inserted probe was
assessed on the morning of day 1, before the start of the
infusion, using the retrodialysis method by perfusing a
Ringer’s solution containing 20 lg/mL of carboplatin
through each inserted probe at a ﬂow rate of 0.5 lL/min
(patient 1 perfused at 0.5 and 1.0 lL/min). After equili-
bration for 15–30 min, 3–5 dialysate samples were
collected every 30 min and processed as described above.
The recovery (Eq. 2) was calculated as the mean of the
three to ﬁve observations.
Microdialysis sampling
As there is a constant ﬂow of Ringer’s solution through the
membrane of the catheter, dialysate is sampled continu-
ously. Samples are collected in microvials (Fig. 1b) during
sample periods varying from 1 h during and shortly after
the carboplatin infusion up to 3 h at later time points.
Samples were stored directly at the bed-side of the patient
at T\-20C. The dialysates were collected by centrifu-
gation of the microvials upside down in micro-centrifuge
reaction vials for 1 min at 5009g, after which they were
stored at T\-70C until analysis.
Cancer Chemother Pharmacol (2009) 64:509–516 511
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For carboplatin plasma pharmacokinetic analysis, blood
samples were collected in the presence of lithium heparin
as anticoagulant at the following time points: before the
start of the intravenous carboplatin infusion, 30 min after
to start of infusion, at the end of the 1 h infusion and at 1,
2, 4, 6, 8, 11, 23, 35 and 47 h after the end of infusion.
Within 15 min after collection, plasma was separated by
centrifugation at 3,0009g for 10 min. Subsequently, 500-
lL aliquots of the plasma supernatant were mixed with 1.0-
mL aliquots of ice-cold (-20C) ethanol and stored at
T\-20C. Ethanolic supernatant was collected by cen-
trifugation at 18,0009g for 5 min after which the clear
supernatant was stored at T\-70C until analysis. The
remaining plasma supernatant, for the analysis of carbo-
platin-derived total platinum, was stored at T\-70C
until analysis.
Carboplatin analysis
For the analysis of carboplatin-derived platinum in dialy-
sate, the methodology was validated in the range of
0.0500–1.00 lg/mL (Method 1) and 0.200–5.00 lg/mL
(Method 2) platinum in Ringer’s solution. For Method 1,
an aliquot of 100 lL dialysate was mixed with an aliquot
of 20 lL 1.0% HNO3 (v/v), while for Method 2, an aliquot
of 20 lL dialysate was mixed with an aliquot of 100 lL
0.2% HNO3 (v/v). A volume of 20 lL, in duplicate, was
subsequently injected onto the graphite furnace of a Perkin
Elmer Model 4110 ZL atomic absorption spectrophotom-
eter (Uberlingen, Germany). Platinum peak areas were
measured at 265.9 nm. The lower limit of quantitation was
established at 0.0500 lg/mL carboplatin-derived platinum
for Method 1 and at 0.200 lg/mL for Method 2.
Plasma concentrations of unbound carboplatin-derived
platinum were determined according to a method as
described for cisplatin-derived platinum [19]. This method
was found to be equivalent to the ultraﬁltration procedure
as described earlier by Ma and Johnsson [20, 21] and has
been validated in our laboratory by direct comparison of
ultraﬁltration and ethanolic deproteinization On the day of
analysis, aliquots of 1,000 lL of the ethanolic supernatant
were evaporated to dryness under nitrogen at T = 80C,
and the residue was reconstituted in 200 lL diluent (i.e.
water containing 0.2% (v/v) Triton X-100 and 0.06% (w/v)
cesium chloride), from which subsequent aliquots of 20 lL
were injected onto the graphite furnace as described above.
The lower limit of quantitation was established at
0.0300 lg/mL.
For total platinum analysis, plasma aliquots were accu-
rately sixfold diluted in diluent (i.e. 100 lL plasma mixed
with 500 lL diluent) from which subsequent aliquots of
20 lL were also injected onto the graphite furnace. The
lower limit of quantitation for total carboplatin-derived
platinum in plasma was established at 0.200 lg/mL.
Pharmacokinetic data analysis
Individual pharmacokinetic parameters for both total and
unbound carboplatin-derived platinum in plasma as well as
for carboplatin-derived platinum in dialysate were esti-
mated using noncompartmental analysis using the software
program WinNonLin 5.0 (Pharsight, CA, USA).
Results
Patients and microdialysis technique
Nine patients were included in the study between March
and October 2007 and six patients were assessable for
pharmacokinetic analysis of carboplatin in the ECF of
tumor tissue. One patient never started therapy because of
Start of 
infusion
Wash-out
Assessment of 
recovery 
Probe insertion 
Day 0 
00:00 12:00
Day 1 
00:00 12:00
Day 2 
00:00 12:00
Day 3 
00:00 12:00 00:00
Microdialysis and 
blood sampling 
Fig. 2 Time frame describing order of procedures
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123rapidly progressing disease. In another patient, there was
leakage of the microdialysis catheter which led to inade-
quate sampling and therefore, catheters at both tumor and
healthy tissue were removed. A third patient was consid-
ered non-evaluable because of a highly variable and
decreasing recovery. The mean of the ﬁve recovery sam-
ples in that patient was 43.4% with a SD of 9.8%, with an
manifest decrease in time. A summary of demographic
characteristics of the six patients assessable for pharma-
cokinetic analysis in the ECF of tumor tissue is presented
in Table 1.
Probe recovery
Microdialysis is not performed under equilibrium condi-
tions, so the concentration of the drug in the dialysate will
be different from that in the ECF of tumor tissue. The
relative recovery refers to the relation between the drug
concentration in the dialysate and the estimated ECF drug
concentration and is used to calculate the actual concen-
tration in the ECF [17].
From initial in vitro recovery experiments (data not
shown), it was anticipated that the microdialysis study
could be performed at a ﬂow rate of 1.0 lL/min. At this
ﬂow rate, the recovery of carboplatin-derived platinum in
tumor tissue of the ﬁrst studied patient was low with a
value of 26.5 ± 3.0%. In this patient the ﬂow rate was
subsequently decreased to 0.5 lL/min resulting in a higher
recovery of 44.8 ± 2.5%. All subsequent patients were
dialyzed at a ﬂow rate of 0.5 lL/min and after equilibration
for 15–30 min, 3–5 dialysate samples were collected every
30 min.
As shown in Table 2, the in vitro recoveries in the
subsequently performed experiments were found to be
higher compared to that observed in vivo recoveries, with
values in the range of 94–98% observed at a ﬂow rate of
0.5 lL/min. By increasing the ﬂow rates to 1.0 and
2.0 lL/min, values of 81.4 ± 3.1 and 61.9 ± 1.2% were
observed, respectively. The in vitro recovery was
independent of the concentration tested and the method
used, was found to be constant over three studied days
and suggested carboplatin did not signiﬁcantly bind to the
microdialysis catheter.
At a ﬂow rate of 0.5 lL/min, the in vivo recovery in the
six tumor tissue evaluable patients varied between 44.8 and
75.8% (Table 3) and was found to be very constant in each
individual patient. The recovery in adipose subcutaneous
tissue in the three normal tissue evaluable patients ranged
between 25.5 and 62.9% (Table 3). In the remaining cases,
one catheter was removed because of leakage, while in
another patient due to incorrect ﬂow setting of the pump,
variable dialysate volumes and, as a result, highly variable
recoveries were observed. In patient 6, recovery decreased
in subsequent dialysates, with a extremely low recovery of
0.4% in the ﬁfth sample taken.
Pharmacokinetics
In Table 3, a summary of the pharmacokinetic data of
carboplatin-derived total and unbound platinum in plasma
as well as unbound platinum in the ECF of tumor and
adipose normal tissue is presented. As shown in Fig. 3, the
pharmacokinetic proﬁles of unbound platinum in the ECF
of tumor and adipose tissue are identical to the proﬁles of
unbound platinum in the plasma compartment. Carboplatin
thus well distributed to the tumor and adipose tissue, while
no sequestration of the drug in the ECF of the tissues was
observed.
Discussion
Previously, several studies have explored microdialysis in
cancer patients in order to study tissue PK of anti-tumor
drugs. However in these studies, sampling was only con-
ducted over a limited period of time (maximum of 4 h). In
this study, we have shown that microdialysis in cancer
patients is also feasible for prolonged periods of time
without restriction of patients’ mobility. This allows
examining anti-tumor drugs in more detail, in particular, Table 1 Patient demographics of the six patients
Patient Age Gender Tumor type Tumor probe site
a
1 49 F Melanoma Thoracic wall
2 31 M Melanoma Leg
3 53 M ACUP Cervical lymph node
4 63 M Eccrine carcinoma Axilla
5 65 M Esophagus
carcinoma
Supraclavicular lymph
node
6 57 F ACUP Thoracic wal
ACUP adenocarcinoma of unknown primary
a Probes in subcutaneous normal adipose tissue were all placed in the
abdomen
Table 2 In vitro recovery of carboplatin at a ﬂow rate of 0.5 lL/min
(data are presented as mean ± SD of three measurements)
20 lg/mL carboplatin 2.0 lg/mL carboplatin
Extr. Rec. (%) Retrodialysis (%) Extr. Rec. (%)
Day 1 95.7 ± 1.9 ND ND
Day 2 94.1 ± 4.1 96.2 ± 0.9 ND
Day 3 95.5 ± 3.6 ND 97.9 ± 1.4
Extr. Rec. extraction recovery
Cancer Chemother Pharmacol (2009) 64:509–516 513
123those drugs with a relative slow clearance such as
carboplatin.
With regard to the obtained pharmacokinetic data,
results show fairly identical PK curves of unbound carbo-
platin at both the tumor site and in plasma. Although
consistent with previous ﬁndings of Blochl-Daum et al. [8]
in which PK data were obtained only up to 4 h after
administration of carboplatin, the similar AUCs of
unbound carboplatin in plasma and tumor ECF of all
studied patients were unexpected. For carboplatin, inter-
nalization of the compound into (the nucleus of) the cell is
necessary in order to induce the formation of toxic plati-
num–DNA adducts, resulting in cell cycle arrest and/or cell
death [22]. Due to fragile vasculature which is more per-
meable than normal vasculature, the interstitial ﬂuid
pressure (IFP) is known to be increased in many solid
tumors compared to adjacent normal tissue. This increased
IFP forms a barrier for transcapillary transport thereby
impairing the uptake of cytotoxic agents [23]. A high
tumor IFP is associated with a poor prognosis in breast
cancer [24, 25], colorectal cancer [24], melanomas [26] and
head and neck tumors [27]. A potentially increased IFP at
the tumor site was thought to be reﬂected by differences
between tumor and plasma exposures of unbound platinum
in our study. A possible explanation for the unexpected
similarity between plasma and tumor pharmacokinetics
could be the co-administration of dexamethasone. Dexa-
methasone (10 mg)—given as standard anti-emetic
treatment—has been shown to lower the IFP of tumors [28]
as a consequence of which carboplatin penetration into the
tumor lesions could be facilitated. This was demonstrated
in a rat model in which the IFP of tumors was signiﬁcantly
lowered after administration of high-dose dexamethasone
resulting in an increase in the uptake of 5-ﬂuorouracil and
in a signiﬁcant reduction of tumor size compared to con-
trols [29].
The recovery in normal subcutaneous adipose tissue was
ﬂuctuating, raising concerns about the feasibility to use
microdialysates from normal adipose tissue as controls.
Theoretically, this could be related to a problematic
Table 3 Summary of pharmacokinetic data carboplatin-derived unbound platinum in plasma and tissue
Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Dose carboplatin (mg) 700 1,150 850 780 700 780
Dose platinum (mg) 368 604 447 410 368 410
Plasma
Cmax (lg/mL) 25.0 21.7 27.1 23.8 19.3 18.8
AUC0–inf ((lg h)/mL)
a 63.3 57.0 59.6 74.2 41.0 53.1
CL (L/h) 5.81 10.6 7.50 5.53 8.98 7.72
Tz
1/2 (h) 4.13 4.02 4.97 5.41 4.04 4.05
Tumor tissue
Probe recovery (%)
b 44.8 ± 2.5
(41.9–46.3; 3)
59.9 ± 2.3
(54.6–60.1; 5)
69.3 ± 1.8
(66.5–71.5; 5)
75.8 ± 4.4
(70.1–80.5; 5)
52.2 ± 2.0
(49.6–53.9; 5)
74.4 ± 4.0
(68.1–77.6; 5)
Cmax (lg/mL) 21.7 21.3 24.8 13.9 13.4 18.3
AUC0–inf ((lg h)/mL)
a 64.3 62.5 65.6 47.2 33.9 57.4
Tz
1/2 (h) 3.64 3.85 2.70 5.68 3.71 3.08
Adipocytic normal tissue
Probe recovery (%)
b NA
c 25.5 ± 1.2
(24.1–26.9; 4)
62.9 ± 5.4
(53.8–68.2; 5)
49.6 ± 2.7
(46.5–53.9; 5)
17.3 ± 9.9
d
(10.1–34.5; 5)
10.8 ± 9.8
e
(21.1 ? 0.4; 5)
Cmax (lg/mL) NA 25.5 19.6 12.5 NA NA
AUC0–inf ((lg h)/mL)
a NA 83.5 51.5 52.9 NA NA
Tz
1/2 (h) NA 3.50 4.26 4.37 NA NA
Ratio’s
AUC tumor/plama 1.02 1.10 1.10 0.64 0.83 1.08
AUC adip. tissue/plasma NA 1.46 0.86 0.71 NA NA
Cmax maximum observed concentration, AUC area under the concentration time curve, CL clearance, Tz
1/2 terminal disposition half-life, NA not
available
a Calculated using observed data up to 24 h after start of infusion
b Mean ± SD (range; number of observations)
c Leakage of probe observed
d Fluctuating and high ﬂow of perfusate
e Highly variable recovery decreasing in subsequent samples
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123catheter implantation with possible disruption of the dial-
ysis membrane, though the implantation procedures were
all carried out quickly without complications. Moreover,
recovery was stable in tumor tissue, where catheter
implantation took place in a similar manner. The under-
lying mechanisms of the relatively low, variable and over-
time decreasing recoveries in adipose normal tissue remain
to be unraveled. A possible explanation could be that
subcutaneous tissue is poorly vascularized compared to
tumor tissue and/or the occurrence of local vasoconstric-
tion during the course of the experiments. Further research
will be necessary to evaluate the deﬁnite role of microdi-
alysis in subcutaneous normal tissue.
As ECF sampling in tumor tissue using microdialysis is
feasible for multiple days, microdialysis might be a valu-
able tool in clinical trials. For instance, it could be
implemented to study intra-tumoral release of drugs from
liposomes or nanosomes. The applicability has been shown
recently in preclinical models for SPI-077, a liposomal
formulation of cisplatin. In contrast to conventional cis-
platin, platinum was not detectable in the ECF of tumor
tissue after the administration of SPI-077, despite sufﬁcient
tumor penetration of the liposomes [30]. Another potential
application area of microdialysis involves the study of
tissue-speciﬁc distribution and metabolism. Enhanced
tumor concentrations of anticancer drugs, e.g. irinotecan,
may be achieved by the administration of prodrugs, which
have to be activated into active metabolites by enzymes in
the tumor. In addition, microdialysis sampling could be
helpful in further disentangling the exact sites of metabo-
lism. Microdialysis may also be applied to unravel
pharmacokinetic–response relationships. For example, in
vivo experiments studying topotecan penetration in two
neuroblastoma xenografts showed that topotecan exposure
in the ECF of the relative sensitive xenograft was 3.5-fold
greater compared to the relative resistant xenograft while
plasma exposures were equivalent. This suggests that the
sensitivity of the xenografts to topotecan is partly related to
the extent of tumor penetration of the drug [31].
In conclusion, we showed the feasibility of microdi-
alysis in ambulant patients for multiple days, which enables
to study tissue pharmacokinetics of anticancer drugs in
normal and malignant tissues in more detail. Microdialysis
could become an important method to measure drug con-
centrations at the site of action, as the procedure is
relatively simple with no restrictions in mobilization of
patients, while data can be obtained with only one catheter
in situ for several days. Nevertheless, it should be men-
tioned that, although microdialysis is a sensitive tool and
enables one to obtain unique intra-tumoral PK information
over time, it is still subject to some technical challenge.
The failed collection of microdialysis data in 2/8 patients
exempliﬁes the limitation of this technique. The data pre-
sented in this study are still limited given the small number
of patients and the high variability in patients. Despite the
high variability, an estimation of the range of drug delivery
to tumor is achieved and this allows clinical determination
if a ‘‘minimum’’ of required concentration is achieved.
In the future, microdialysis could be valuable for addi-
tional PK/PD information in studies evaluating, for
example, liposome- and immunoliposome-based cancer
therapeutics or other carrier-mediated anticancer agents.
The use of microdialysis may also be helpful in optimizing
dosing and administration schedules of anticancer agents in
the selection of new cytotoxic agents with the most
favorable delivery proﬁle and to gain more insights into
mechanisms conferring drug resistance.
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inum in plasma (open circles, dashed line) and unbound platinum in
plasma (open circles, solid line), ECF of tumor (ﬁlled circles) and
ECF of normal adipose tissue (ﬁlled triangles) in the six evaluable
patients
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